Zelgen Submits a Marketing Application in China for Gecacitinib in Ankylosing Spondylitis
October 16, 2026
Source: drugdu
31
On October 14, 2026, Zekjing Biotechnology (688266.SH) announced that it had submitted a third marketing application for gecacitinib to the National Medical Products Administration for the treatment of active ankylosing spondylitis.
Gecacitinib is a novel JAK inhibitor independently developed by the company, which owns the intellectual property rights to the product. Previously, the drug had been approved for marketing by the National Medical Products Administration for two indications: the treatment of intermediate- to high-risk myelofibrosis and severe alopecia areata in adults. The myelofibrosis indication has been included in the 2025 National Reimbursement Drug List.
Ankylosing spondylitis is an arthritis characterized by long-term inflammation of the spinal joints, typically manifesting as inflammation of the sacroiliac joints and spinal entheses. The Chinese market for ankylosing spondylitis drugs is projected to reach RMB 17 billion by 2025, with a compound annual growth rate of 12.1% from 2020 to 2025.
Source: https://mp.weixin.qq.com/s?__biz=MzA5Njc0MTAxOQ==&mid=2650033491&idx=2&sn=0acfe69713aae899421bc4c8d33101c2&chksm=89939f3bf89bb9f002129378fbe4bfc53f860
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Vir Biotechnology Enters Multi-Program Collaboration with Gilead Sciences to Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors October 16, 2026
- Subsidiary’s YKYY036 Injection Receives Clinical Trial Approval from NMPA and FDA October 16, 2026
- BioNTech’s mRNA Cancer Vaccine BNT113 Falls Short of Primary Endpoint in Phase 3 Trial October 16, 2026
- Foghorn Therapeutics’ Collaboration Terminated by Eli Lilly; Company to Lay Off 40% of Its Workforce October 16, 2026
- Visara (USA) Acquires Overseas Rights to Haite Bio’s HT006.2.2 Eye Drops October 16, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
